These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34586414)

  • 1. Vaptans or voluntary increased hydration to protect the kidney: how do they compare?
    Bankir L; Guerrot D; Bichet DG
    Nephrol Dial Transplant; 2023 Feb; 38(3):562-574. PubMed ID: 34586414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V
    Taveau C; Chollet C; Bichet DG; Velho G; Guillon G; Corbani M; Roussel R; Bankir L; Melander O; Bouby N
    Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E127-E135. PubMed ID: 27998960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.
    Hew-Butler T; Hummel J; Rider BC; Verbalis JG
    Am J Physiol Regul Integr Comp Physiol; 2014 Aug; 307(4):R366-75. PubMed ID: 24944242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a functional V
    Hus-Citharel A; Bouby N; Corbani M; Mion J; Mendre C; Darusi J; Tomboly C; Trueba M; Serradeil-Le Gal C; Llorens-Cortes C; Guillon G
    Am J Physiol Renal Physiol; 2021 Sep; 321(3):F305-F321. PubMed ID: 34282956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.
    Bankir L
    Cardiovasc Res; 2001 Aug; 51(3):372-90. PubMed ID: 11476728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
    Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
    J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.
    Aoyagi T; Izumi Y; Hiroyama M; Matsuzaki T; Yasuoka Y; Sanbe A; Miyazaki H; Fujiwara Y; Nakayama Y; Kohda Y; Yamauchi J; Inoue T; Kawahara K; Saito H; Tomita K; Nonoguchi H; Tanoue A
    Am J Physiol Renal Physiol; 2008 Jul; 295(1):F100-7. PubMed ID: 18448596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
    Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
    J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering RNA-mediated functional silencing of vasopressin V2 receptors in the mouse kidney.
    Hassan A; Tian Y; Zheng W; Ji H; Sandberg K; Verbalis JG
    Physiol Genomics; 2005 May; 21(3):382-8. PubMed ID: 15784697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Residence Time Peptide Antagonist for the Vasopressin V
    Xiong X; Wang N; Zhang Y; Zhao W; Pang N; Fu K; Zhou N; Zhou X; Guo D
    J Med Chem; 2024 Apr; 67(7):5935-5944. PubMed ID: 38509003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation.
    Park F; Mattson DL; Skelton MM; Cowley AW
    Am J Physiol; 1997 Jul; 273(1 Pt 2):R243-51. PubMed ID: 9249556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin V2 receptor, tolvaptan, and ERK1/2 phosphorylation in the renal collecting duct.
    Khan S; Raghuram V; Chen L; Chou CL; Yang CR; Khundmiri SJ; Knepper MA
    Am J Physiol Renal Physiol; 2024 Jan; 326(1):F57-F68. PubMed ID: 37916285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct.
    Hus-Citharel A; Bodineau L; Frugière A; Joubert F; Bouby N; Llorens-Cortes C
    Endocrinology; 2014 Nov; 155(11):4483-93. PubMed ID: 25157454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
    Gattone VH; Maser RL; Tian C; Rosenberg JM; Branden MG
    Dev Genet; 1999; 24(3-4):309-18. PubMed ID: 10322639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Giełdoń A; Kaźmierkiewicz R; Slusarz R; Ciarkowski J
    J Comput Aided Mol Des; 2001 Dec; 15(12):1085-104. PubMed ID: 12160092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptation to sustained high plasma vasopressin in water and electrolyte homeostasis in the rat transgenic for the metallothionein-vasopressin fusion gene.
    Yokoi H; Nagasaki H; Tachikawa K; Arima H; Murase T; Miura Y; Hirabayashi M; Oiso Y
    J Endocrinol; 2002 Apr; 173(1):23-33. PubMed ID: 11927381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.